APSR2026-980

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP10-030
P30
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1243286-46904-Chiesi TRIPHY APSR26 poster (17 Oct 2026)_432780.pdf
Format: PDF Only
07. COPD
12

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Jinping Zheng * The First Affiliated Hospital of Guangzhou Medical University National Center for Clinical Research of Respiratory Disease Guangzhou China
Luqian Zhou - The First Affiliated Hospital of Guangzhou Medical University National Center for Clinical Research of Respiratory Disease Guangzhou China
Haiyan Shao - Wenling First People 's Hospital . Wenling China
Weiguo Xu - Mianyang Central Hospital . Mianyang China
Shuangmei Zhang - Huzhou Central Hospital . Huzhou China
Liang Chen - Beijing Jingmei Group General Hospital . Beijing China
Yiming Yu - The First Affiliated Hospital of Ningbo University . Ningbo China
Xiuzhu Zhang - Chiesi Pharmaceutical Consulting (Shanghai) Co. Ltd Global Clinical Development Shanghai China
Giovanni Giorli - Chiesi Farmaceutici SpA Global Clinical Development Parma Italy
Cissy Zhu - Chiesi Pharmaceutical Consulting (Shanghai) Co. Ltd Global Clinical Development Shanghai China
Alicia Gayle - Chiesi Ltd Global Clinical Development Manchester United Kingdom
Kim Lu - Chiesi Farmaceutici SpA Global Clinical Development Parma Italy
 
 
 
Presenting Author Details
Jinping
Zheng
jpzhenggy@163.com
+8618928868238
61-70
China
Original Research
Real World Effectiveness and Safety of Single Inhaler Triple Therapy with Trimbow® pMDI in COPD: Results from the TRIPHY Study in China
Maximum 25 words
Abstract Content
Real world evidence for single inhaler triple therapy in chronic obstructive pulmonary disease (COPD) in China as well as many parts of the world are limited. TRIPHY evaluated the effectiveness, safety, and adherence of Trimbow® pressurised metered dose inhaler (pMDI; beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide [BDP/FF/GB]) in a routine clinical setting.
TRIPHY was a 12 week, multicentre, single cohort, ambidirectional non-interventional study conducted at 19 sites in China from 2024 to 2025. Patients (≥40 years) with COPD who initiated BDP/FF/GB within 12 weeks prior to enrolment were included. The primary endpoint was change in COPD Assessment Test (CAT) total score from baseline. Secondary endpoints included lung function (FEV₁, FEV₁% of predicted, peak expiratory flow [PEF]) and safety outcomes. Treatment adherence was also assessed (Test of Adherence to Inhaler, TAI).
362 subjects were enrolled (mean age 67.7 years; 83.7% male). The mean CAT total score decreased from 19.1 at baseline to 9.4 at Week 12, mean change −9.8 (95% CI: −10.6, −9.1; p<0.0001). 72.4% of subjects were CAT responders (≥2 point reduction). Lung function improved significantly at week 12, with mean increases of 0.222 L in FEV₁ (95% CI: 0.183, 0.261, p<0.001), 8.9% in FEV₁% of predicted(95% CI: 7.5%, 10.4%, p<0.001), 0.96 L/s in PEF (95% CI: 0.429, 1.500, p<0.001). Improvements were, consistent across enrolment scenarios and smoking status groups. At Week 12, 40.9% of patients demonstrated good adherence (TAI=50). Treatment emergent adverse events occurred in 22.7% of patients, serious adverse events in 3.9%, and adverse drug reactions in 1.9%. No deaths were observed.
In this real world study in China, Trimbow® pMDI was associated with clinically meaningful improvements in symptoms and lung function and a favourable safety profile, supporting its effective and safe use in Chinese patients with COPD.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
 
maximum 3 keywords and no abbreviations, separated by commas
 
326